| AbbVie |
00074101756 |
ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) copackaged for oral use--56 capsules; 4 blister-pack carton: 28 capsules of elagolix 300 mg, estradiol 1 mg, norethindrone acetate 0.5 mg; 28 capsules of elagolix 300mg |
2020-06-22 |
907.3900 |
* ORIAHNN will be marketed for premenopausal women suffering from heavy menstrual bleeding associated with uterine leiomyomas (fibroids).
* The Wholesale Acquisition Cost (WAC) of ORIAHNN is $907.39 per a month supply. Pricing is the same for ORIAHNN as the previously approved AbbVie elagolix product, ORILISSA, which is indicated for moderate-to-severe endometriosis related pain.
* To date AbbVie has not filed for regulatory approval of ORIAHNN in jurisdictions outside the United States. |
None |
None |
None |
None |
None |
None |
None |
None |
Response on estimated volume of patients who may be prescribed the drug (see Cal. Health & Saf. Code § 96076(b)(2):
ORIAHNN is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Based upon a review of published analyses of uterine fibroid prevalence approximately .3% of pre-menopausal women suffer from heavy menstrual bleeding associated with uterine fibroids, have not had a hysterectomy, and are seeking treatment for their condition: approximately 200,000 women. See Fuldeore et al, Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. Int J Women’s Health. 2017; 9: 403–411; Borah et al, The Impact of Uterine Leiomyomas: A National Survey of Affected Women. Am J Obstet Gynecol. 2013 Oct; 209(4): 319.e1–319.e20; Wang et al. Burden of Heavy Menstrual Bleeding Associated with Uterine Fibroids: Retrospective Analysis of A Large Commercially Insured Population in the US. Poster presented at Academy of Managed Care Pharmacy (AMCP) Nexus Annual Meeting 2019. Journal of Managed Care & specialty Pharmacy, Supplement. Vol 25; Number 10-a. October 2019. ORIAHNN may be prescribed for that fraction of those patients for whom a physician and patient in consultation may consider this treatment appropriate.
Additional Context for Report
ORIAHNN was developed by AbbVie under its collaboration agreement with Neurocrine Biosciences, with research and development funded and conducted in part by AbbVie. On June 16, 2010 AbbVie publicly announced its collaboration with Neurocrine Biosciences for the development of elagolix. The parties worked together on a collaborative development program through 2012 with funding provided by AbbVie, after which time AbbVie assumed sole responsibility for all development and commercialization activities. AbbVie made an upfront payment of $75 million and funded all ongoing development activities. Under the agreement, Neurocrine is eligible to receive additional milestone payments of approximately $530 million for the achievement of development, regulatory and commercial milestones, funding for certain internal collaboration expenses, and royalty payments on any future product sales. |
None |
| Accord Healthcare, Inc. |
16729043445 |
Daptomycin (SDV); 350 mg; 10 pk [lyo] Vial |
2020-02-27 |
680.0000 |
Marketing: Accord markets generic Daptomycin in a ten pack of 350 mg vials. The drug is therapeutically equivalent to the innovator (brand) drug. As such, Accord relies on the safety and efficacy findings of the FDA with respect to the innovator drug. Accord does not interact with physicians and markets solely to distributors, hospital groups, group purchasing organizations and like entities based solely on price and availability. Accord does not market based on any aspects of the drug itself. Further, Accord does not aim to treat a certain number of patients, it simply looks at the size of the total market and aims to achieve a certain market share.
Pricing: In order to set the wholesale acquisition price (“WAC”) of Daptomycin, Accord matched the lowest generic WAC available at the time of its launch. Accord uses subscription-based services, such as Medi-Span Price Rx to obtain this information. Accord launched single vials of this product last year and set the WAC for the new NDC of 10 packs at equivalent pricing. |
None |
None |
None |
None |
None |
None |
None |
None |
Accord did not acquire the ANDA for Daptomycin, the generic product was developed in house.
Note that Accord is required to and does follow the innovator with respect to its prescribing information, including dosage. Accord does not interact with healthcare providers or advise on usage, other than to direct any questions to Accord’s prescribing information. Accord does not have information as to what constitutes a 30 day supply of Daptomycin but is reporting the WAC of 10 pack of vials, which is the unit by which Accord sells the drug.
Accord does not have data related to Estimated Number of Patients for Daptomycin 10 packs. Although there may be publications that show statistical data in previous years, Accord does not use this data to make business decisions. Further, Accord has not been informed of the methods or procedures as to how this statistical information was developed, nor does Accord have internal methods or procedures to estimate a reasonable number of patients with a disease state and, therefore, cannot answer this question with any level of accuracy that is needed in order to comply with the requirement. In making decisions about whether to market a product, Accord does not consider patient number, it considers total market size based on dollar amount. It is a generic manufacturer and as such does not manufacture or market products based upon specific conditions or to sets of patients, but based upon price and availability only. Finally, the specific details regarding number of patients treated by a given drug in the previous year are not freely available to the public. |
None |
| Accord Healthcare, Inc. |
16729044210 |
Cinacalcet Tab; 90 mg; 30 ct |
2020-06-16 |
925.6900 |
Marketing: Accord markets generic Cinacalcet in both 30 and 90 tablet count bottles. The drug is therapeutically equivalent to the innovator (brand) drug. As such, Accord relies on the safety and efficacy findings of the FDA with respect to the innovator drug. Accord does not interact with physicians and markets solely to distributors, hospital groups, group purchasing organizations and like entities based solely on price and availability. Accord does not market based on any aspects of the drug itself. Further, Accord does not aim to treat a certain number of patients, it simply looks at the size of the total market and aims to achieve a certain market share.
Pricing: In order to set the wholesale acquisition price (“WAC”) of Cinacalcet, Accord matched the lowest generic WAC available at the time of its launch. Accord uses subscription-based services, such as Medi-Span Price Rx to obtain this information. |
None |
0 |
None |
None |
None |
None |
None |
None |
Accord did not acquire the NDC for Cinacalcet, the generic product was developed in house.
Note that Accord is required to and does follow the innovator with respect to its prescribing information, including dosage. Accord does not interact with healthcare providers or advise on usage, other than to direct any questions to Accord’s prescribing information. Accord does not have information as to what constitutes a 30 day supply of Cinacalcet but is reporting the WAC of both 30 and 90 tablet count bottles, which are the units by which Accord sells the drug. |
None |
| Accord Healthcare, Inc. |
16729044015 |
Cinacalcet Tab; 30 mg; 90 ct |
2020-06-19 |
925.7100 |
Marketing: Accord markets generic Cinacalcet in both 30 and 90 tablet count bottles. The drug is therapeutically equivalent to the innovator (brand) drug. As such, Accord relies on the safety and efficacy findings of the FDA with respect to the innovator drug. Accord does not interact with physicians and markets solely to distributors, hospital groups, group purchasing organizations and like entities based solely on price and availability. Accord does not market based on any aspects of the drug itself. Further, Accord does not aim to treat a certain number of patients, it simply looks at the size of the total market and aims to achieve a certain market share.
Pricing: In order to set the wholesale acquisition price (“WAC”) of Cinacalcet, Accord matched the lowest generic WAC available at the time of its launch. Accord uses subscription-based services, such as Medi-Span Price Rx to obtain this information. |
None |
0 |
None |
None |
None |
None |
None |
None |
Accord did not acquire the NDC for Cinacalcet, the generic product was developed in house.
Note that Accord is required to and does follow the innovator with respect to its prescribing information, including dosage. Accord does not interact with healthcare providers or advise on usage, other than to direct any questions to Accord’s prescribing information. Accord does not have information as to what constitutes a 30 day supply of Cinacalcet but is reporting the WAC of both 30 and 90 tablet count bottles, which are the units by which Accord sells the drug. |
None |
| Accord Healthcare, Inc. |
16729044115 |
Cinacalcet Tab; 60 mg; 90 ct |
2020-06-19 |
1851.3900 |
Marketing: Accord markets generic Cinacalcet in both 30 and 90 tablet count bottles. The drug is therapeutically equivalent to the innovator (brand) drug. As such, Accord relies on the safety and efficacy findings of the FDA with respect to the innovator drug. Accord does not interact with physicians and markets solely to distributors, hospital groups, group purchasing organizations and like entities based solely on price and availability. Accord does not market based on any aspects of the drug itself. Further, Accord does not aim to treat a certain number of patients, it simply looks at the size of the total market and aims to achieve a certain market share.
Pricing: In order to set the wholesale acquisition price (“WAC”) of Cinacalcet, Accord matched the lowest generic WAC available at the time of its launch. Accord uses subscription-based services, such as Medi-Span Price Rx to obtain this information. |
None |
0 |
None |
None |
None |
None |
None |
None |
Accord did not acquire the NDC for Cinacalcet, the generic product was developed in house.
Note that Accord is required to and does follow the innovator with respect to its prescribing information, including dosage. Accord does not interact with healthcare providers or advise on usage, other than to direct any questions to Accord’s prescribing information. Accord does not have information as to what constitutes a 30 day supply of Cinacalcet but is reporting the WAC of both 30 and 90 tablet count bottles, which are the units by which Accord sells the drug. |
None |
| Accord Healthcare, Inc. |
16729044215 |
Cinacalcet Tab; 90 mg; 90 ct |
2020-06-25 |
2777.0700 |
Marketing: Accord markets generic Cinacalcet in both 30 and 90 tablet count bottles. The drug is therapeutically equivalent to the innovator (brand) drug. As such, Accord relies on the safety and efficacy findings of the FDA with respect to the innovator drug. Accord does not interact with physicians and markets solely to distributors, hospital groups, group purchasing organizations and like entities based solely on price and availability. Accord does not market based on any aspects of the drug itself. Further, Accord does not aim to treat a certain number of patients, it simply looks at the size of the total market and aims to achieve a certain market share.
Pricing: In order to set the wholesale acquisition price (“WAC”) of Cinacalcet, Accord matched the lowest generic WAC available at the time of its launch. Accord uses subscription-based services, such as Medi-Span Price Rx to obtain this information. |
None |
0 |
None |
None |
None |
None |
None |
None |
Accord did not acquire the NDC for Cinacalcet, the generic product was developed in house.
Note that Accord is required to and does follow the innovator with respect to its prescribing information, including dosage. Accord does not interact with healthcare providers or advise on usage, other than to direct any questions to Accord’s prescribing information. Accord does not have information as to what constitutes a 30 day supply of Cinacalcet but is reporting the WAC of both 30 and 90 tablet count bottles, which are the units by which Accord sells the drug. |
None |
| Acella Pharamceuticals, LLC |
42192061916 |
Naproxen Suspension: 125 mg/5 mL (contains 39 mg sodium): Available in 1 pint (473 mL) light-resistant bottles; Type 0: Not a Combination Product |
2020-11-12 |
837.0000 |
None |
1 |
7250 |
None |
None |
2020-11-11 |
0.0000 |
1 |
This product is a licensed Authorized Generic. There was no acquisition price paid by Acella, however, Acella does share revenues with the Licensor. Factors affecting the acquisition price are only know to a small group of individuals at Acella – namely the Commercial, Government Pricing, Compliance and Legal departments consisting of less than 10 people within those departments with access to that information. |
This product was not launched on November 12, 2020 as indicated in Medispan, the various compendiums and our recent New Drug Notice filed with OSHPD. While we did sign the license agreement to market this product on November 11, 2020, we did not have the labeling or inventory ready to market/sell until December 2, 2020. The incorrect Marketing Start Date listed in DailyMed and in the compendiums was a result of confusion in our regulatory department regarding the business realities of the execution of the license agreement versus truly marketing the product with available inventory. Our understanding is that the “introduced to market date” for OSHPD should be consistent with the FDA “Marketing Start Date” reported to the FDA and reflected in DailyMed and the compendiums. |
None |
| Acerus Pharmaceuticals Corporation |
42667551101 |
Natesto Nasal Gel 5.5 MG/ACT/7.32GM |
2020-07-20 |
275.0000 |
None |
1 |
634211 |
None |
None |
None |
None |
None |
None |
This Drug was not acquired. 30 day supply is 3 packs @ a WAC of $275.08 each |
None |
| Aimmune Therapeutics |
71881011313 |
PALFORZIA Initial Dose Escalation Card -- 0.5 mg-6 mg |
2020-03-10 |
30.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881011130 |
PALFORZIA Maintenance Dosing Pack -- 300 mg, 30 count sachet |
2020-03-10 |
890.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010345 |
PALFORZIA Up-Dosing Pack -- 12 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010730 |
PALFORZIA Up-Dosing Pack -- 120 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010860 |
PALFORZIA Up-Dosing Pack -- 160 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010415 |
PALFORZIA Up-Dosing Pack -- 20 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010930 |
PALFORZIA Up-Dosing Pack -- 200 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881011060 |
PALFORZIA Up-Dosing Pack -- 240 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010145 |
PALFORZIA Up-Dosing Pack -- 3 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881011115 |
PALFORZIA Up-Dosing Pack -- 300 mg, 15 count sachet |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010530 |
PALFORZIA Up-Dosing Pack -- 40 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010290 |
PALFORZIA Up-Dosing Pack -- 6 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Aimmune Therapeutics |
71881010660 |
PALFORZIA Up-Dosing Pack -- 80 mg |
2020-03-10 |
445.0000 |
Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.
Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients. |
None |
1600000 |
1 |
None |
None |
None |
None |
None |
In 2017, 1.25 million Peanut Allergy patients ages 4-17 were diagnosed in the United States, and today is estimated to affect more than 1.6 million children and teens. |
None |
| Ajanta Pharma USA, Inc. |
27241015919 |
Valganciclovir Hydrochlor Oral Sol 100ml |
2020-02-17 |
800.2600 |
None |
1 |
321 |
None |
None |
None |
None |
None |
None |
This drug was not acquired. Please note that Ajanta has no information as to what the total market may be and no has no way currently of knowing what the total market may be and no data to make a reasonable guess. Ajanta is only able to certify their estimates of patients using the drugs based on their sales. |
None |
| Alexion Pharmaceuticals |
25682002501 |
ULTOMIRIS is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). |
2020-10-09 |
6404.0000 |
Alexion prices both 3 mL and 11 mL vials at-parity-per-milligram to the existing ULTOMIRIS 10mg (300 mg/30 mL) vial that is available on the market. We have an established commercial organization that supports our marketed products in the U.S., Europe, Japan, Latin America, Asia Pacific countries, and other territories. We employ a sales force and commercial marketing functions to ensure that health care providers are informed about our products. |
None |
3936 |
None |
None |
None |
None |
None |
None |
Based on reports in the published medical literature, the prevalence of PNH ranges from 0.5 to 2 per million people, and the prevalence of aHUS ranges from 2 to 10 per million people. Based on a US population of 328 million, the treatable population for each condition may be as large as 656 people for PNH and 3280 people for aHUS. |
None |
| Alexion Pharmaceuticals |
25682002801 |
ULTOMIRIS is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). The dosage form and strength is 1,100 mg/11 mL (100 mg/mL) in a single-dose vial. Package size is 11 ml |
2020-10-09 |
23481.3300 |
Alexion prices both 3 mL and 11 mL vials at-parity-per-milligram to the existing ULTOMIRIS 10mg (300 mg/30 mL) vial that is available on the market. We have an established commercial organization that supports our marketed products in the U.S., Europe, Japan, Latin America, Asia Pacific countries, and other territories. We employ a sales force and commercial marketing functions to ensure that health care providers are informed about our products. |
None |
3936 |
None |
None |
None |
None |
None |
None |
Based on reports in the published medical literature, the prevalence of PNH ranges from 0.5 to 2 per million people, and the prevalence of aHUS ranges from 2 to 10 per million people. Based on a US population of 328 million, the treatable population for each condition may be as large as 656 people for PNH and 3280 people for aHUS. |
None |
| Allergan |
00023650110 |
Ubrelvy Oral Tablet 100 MG, 10 tabs per Pack |
2020-01-21 |
850.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising in the migraine community, as well as promoting to appropriate healthcare professionals and patients. The pricing plan has a WAC/ list price set at $850 per 10ct package. The list price of Ubrelvy is not reflective of discounts and rebates which may be available to patients and payers including but not limited to, Medicaid, Medicare, and commercial insurance. |
None |
31000000 |
None |
None |
2015-07-06 |
250000000.0000 |
None |
Allergan acquired exclusive worldwide rights to develop and commercialize certain products, including Ubrelvy (ubrogepant), from Merck Sharp & Dohme Corp. on July 6, 2015 for $250M. Allergan remained responsible for Phase III Clinical Trials and continues to remain responsible for further development of Ubrelvy (ubrogepant). |
Migraine is a chronic disease with episodic attacks defined by neurological symptoms such as headache pain, sensitivity to light and sound, and nausea. Migraine is highly prevalent, affecting approximately 31 million Americans, and is associated with significant disability leading to high personal, family, occupational, societal, and economic burden. Based on the current standard of care, there are still unmet needs for new acute treatments for migraine.Each NDC could be used for any eligible patient. |
None |
| Allergan |
00023649810 |
Ubrelvy Oral Tablet 50 MG, 10 tabs per Pack |
2020-01-21 |
850.0000 |
While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising in the migraine community, as well as promoting to appropriate healthcare professionals and patients. The pricing plan has a WAC/ list price set at $850 per 10ct package. The list price of Ubrelvy is not reflective of discounts and rebates which may be available to patients and payers including but not limited to, Medicaid, Medicare, and commercial insurance. |
None |
31000000 |
None |
None |
2015-07-06 |
250000000.0000 |
None |
Allergan acquired exclusive worldwide rights to develop and commercialize certain products, including Ubrelvy (ubrogepant), from Merck Sharp & Dohme Corp. on July 6, 2015 for $250M. Allergan remained responsible for Phase III Clinical Trials and continues to remain responsible for further development of Ubrelvy (ubrogepant). |
Migraine is a chronic disease with episodic attacks defined by neurological symptoms such as headache pain, sensitivity to light and sound, and nausea. Migraine is highly prevalent, affecting approximately 31 million Americans, and is associated with significant disability leading to high personal, family, occupational, societal, and economic burden. Based on the current standard of care, there are still unmet needs for new acute treatments for migraine. Each NDC could be used for any eligible patient. |
None |
| Allergan |
00023965201 |
Durysta Intraocular Implant 10 MCG |
2020-06-22 |
1950.0000 |
• DURYSTA will be marketed to adults for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
• The Wholesale Acquisition Cost (WAC) of DURYSTA is $1950 per implant.
• To date Allergan has not filed for regulatory approval of DURYSTA in jurisdictions outside the United States. |
None |
None |
None |
None |
None |
None |
None |
None |
Response on estimated volume of patients who may be prescribed the drug (see Cal. Health & Saf. Code § 96076(b)(2):
DURYSTA is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). A 2012 published study identified 2.71 million patients in the US with open angle glaucoma and projected greater than 3 million patients in 2020. See Vajaranant, T et al., The Changing Face of Primary Open-Angle Glaucoma in the United States: Demographic and Geographic Changes From 2011 to 2050, Am. J. of Ophthalmology, 154:303-314 (2012). See also Glaucoma Research Foundation website, at https://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php. DURYSTA may be prescribed for that fraction of patients for whom a physician and patient in consultation may consider this treatment appropriate.
Additional Context for Report
DURYSTA was developed by Allergan. On May 8, 2020 AbbVie Inc. completed its acquisition of Allergan plc at a cost of approximately $63 billion. |
None |
| ALVOGEN |
47781065289 |
TERIPARATIDE INJECTION 250MCG/ML |
2020-06-11 |
2475.0000 |
Alvogen is committed to the highest quality standards for all products and services with the continuous focus on operational efficiency and cost optimization. Alvogen has invested $350,000 nationally in marketing this product, having created and distributed to physicians and pharmacies a detailed flyer with information regarding indications, safety information, contraindications, and the Alvogen Savings Program. Alvogen has also launched an informative, product-specific website for patients and providers alike (http://www.alvogenteriparatide.com). Alvogen utilizes a pricing methodology that takes into account a number of factors, including the cost of the product's acquisition, utilization estimates, the value rendered by this innovative product to patients and their providers, as well as the health care system, and ongoing marketing, manufacturing, and other operational costs. Alvogen also takes into account current market dynamics including competitor products along with the potential entry of generics into the drug class. Alvogen is committed to transparency and access for its products, and undertakes all of its marketing and pricing decisions with those goals in mind. |
None |
10200000 |
None |
None |
2018-06-30 |
2000000.0000 |
None |
Pfenex received an upfront payment of $2.5M for the license and rights. They may be eligible for an additional $25M in support and regulatory milestone payments. |
The price listed in a published compendium does not necessarily reflect the actual price that a particular patient, provider, or payer will pay for this product, which may vary based on mandatory and negotiated discounts, and in accordance with actual patient dosing.
The National Osteoporosis Foundation has estimated approximately 10.2M adults in the United States has osteoporosis, the condition for which this product may be prescribed. That number does not reflect the number of patients who will be prescribed this product, which will be a much lower number (which is not in the public domain or publicly available). |
None |
| American Health Packaging |
60687045901 |
PALIPERIDONE ER TABLET3MG100UD |
2020-01-14 |
1445.6200 |
Create collateral of new item; initiative ABC stream serve; Email collateral to AHP customer base; utilize AHP & ABC inside sales team to create awareness of new item; place collateral in industry publications for visibility to the pharmacy practice |
None |
3500000 |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. Number of patients based on treatment of schizophrenia (https://www.webmd.com/drugs/2/drug-146718/paliperidone-oral/details) and cross referenced at ( https://sardaa.org/resources/about-schizophrenia/#:~:text=Approximately%203.5%20million%20people%20in,is%20at%20least%20partially%20genetic). All the fields that are left blank are due to "Not Applicable". |
None |
| American Health Packaging |
60687047001 |
PALIPERIDONE ER TABLET6MG100UD |
2020-01-14 |
1445.6200 |
Create collateral of new item; initiative ABC stream serve; Email collateral to AHP customer base; utilize AHP & ABC inside sales team to create awareness of new item; place collateral in industry publications for visibility to the pharmacy practice |
None |
3500000 |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. Number of patients based on treatment of schizophrenia (https://www.webmd.com/drugs/2/drug-146718/paliperidone-oral/details) and cross referenced at ( https://sardaa.org/resources/about-schizophrenia/#:~:text=Approximately%203.5%20million%20people%20in,is%20at%20least%20partially%20genetic). All the fields that are left blank are due to "Not Applicable". |
None |
| American Health Packaging |
60687044901 |
SEVELAMER HCL TABLET800MG100UD |
2020-01-22 |
743.7500 |
Create collateral of new item; initiative ABC stream serve; Email collateral to AHP customer base; utilize AHP & ABC inside sales team to create awareness of new item; place collateral in industry publications for visibility to the pharmacy practice |
None |
6000000 |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. Number of patients based on treatment of kidney disease (https://www.webmd.com/drugs/2/drug-16748/sevelamer-hcl-oral/details) and cross referenced at (https://www.cdc.gov/nchs/fastats/kidney-disease.htm). All the fields that are left blank are due to "Not Applicable". |
None |
| American Health Packaging |
68001042485 |
FULVESTRANT INJECTION250MG (50MG/5ML) 25 syr |
2020-02-28 |
1939.0500 |
Gathering Market Intelligence, Setting Competitive pricing for PRxO, executing product launches, managing master data files. |
None |
325000 |
None |
None |
2020-02-25 |
1372.0000 |
None |
BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the quarter total for all units received within the date listed. AHP is the US distributor for Bluepoint product. Amount represented for acquisition is in total US dollars. |
Bluepoint Laboratories is a sibling company with AHP as its sole distributor and is the responsible party for distribution of their products.
Number of patients based on treatment of breast cancer (https://medlineplus.gov/druginfo/meds/a607031.html) and cross referenced at (https://www.breastcancer.org/symptoms/understand_bc/statistics), it is not a representation of AHP's estimated market capture. |
None |
| American Health Packaging |
60687050525 |
AMINOCAPROIC ACID TABLET500MG30UD |
2020-05-18 |
800.0000 |
Create collateral of new item; initiative ABC stream serve; Email collateral to AHP customer base; utilize AHP & ABC inside sales team to create awareness of new item; place collateral in industry publications for visibility to the pharmacy practice |
None |
4500000 |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. Number of patients based on treatment of severe liver disease (https://www.medicinenet.com/aminocaproic_acid-oral/article.htm) and cross referenced at CDC.gov (https://www.cdc.gov/nchs/fastats/liver-disease.htm). All the fields that are left blank are due to "Not Applicable". |
None |
| American Health Packaging |
60687052321 |
POSACONAZOLE DR TABLET100MG30UD |
2020-06-11 |
1415.0000 |
Create collateral of new item; initiative ABC stream serve; Email collateral to AHP customer base; utilize AHP & ABC inside sales team to create awareness of new item; place collateral in industry publications for visibility to the pharmacy practice |
None |
650000 |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. Number of patients based on treatment with chemotherapy (https://www.webmd.com/drugs/2/drug-145142-1598/posaconazole-oral/posaconazole-delayed-release-oral/details) and cross referenced at (https://www.cdc.gov/cancer/preventinfections/providers.htm#:~:text=Each%20year%2C%20about%20650%2C000%20cancer,chemotherapy%20schedules%2C%20and%20even%20death.). All the fields that are left blank are due to "Not Applicable". |
None |
| American Health Packaging |
60687053478 |
Atovaquone Oral Sus 750mg/5mL 5mL |
2020-10-21 |
1245.0000 |
Create collateral of new item; initiative ABC stream serve; Email collateral to AHP customer base; utilize AHP & ABC inside sales team to create awareness of new item; place collateral in industry publications for visibility to the pharmacy practice |
None |
None |
None |
None |
2020-09-21 |
112176.0000 |
None |
As a repackager, AHP does not engage in a licensing agreement with the ANDA holder rather we purchase commercially available batches of drug product and repackage into unit-dose presentations under an AHP NDC. There is no licensing acquisition cost as each batch of product is purchased independently and repackaged in whole-batch quantities per FDA regulations and guidance. Price indicated is for initial receipt of product for launch of the repackaged NDC. |
ESTIMATED # PATIENTS: Patient Information - CANNOT BE DETERMINED: Atovaquone is used for treatment of Pneumocystis pneumonia (reference: https://www.webmd.com/drugs/2/drug-6077/atovaquone-oral/details) and number of patients cannot be quantified per CDC (https://www.cdc.gov/fungal/diseases/pneumocystis-pneumonia) as this information isn’t widely tracked. |
None |
| American Regent |
00517800525 |
ZINC SULFATE INJECTION USP, 25MG/5ML (5MG/ML), PKG OF 25 |
2020-01-28 |
1753.1300 |
We do not have plans to conduct any substantial marketing activities related to the new product. We do not have any plans to conduct any direct-to-consumer advertising for the product. Our marketing efforts to promote the new drug to physicians and other health care professionals are limited to marketing on our website as well as a digital announcement to announce the availability of the new product. The prices negotiated with customers are confidential and not in the public domain or publicly available. American Regent sells its products directly to wholesalers, distributors and closed door pharmacies. American Regent also sells it product indirectly to several entities, including independent pharmacies, managed care organizations, hospitals, etc. These customers, called, "indirect customers," purchase our products primarily through our wholesale customers. The Product has not yet launched in any international jurisdiction. |
None |
26250 |
None |
None |
None |
None |
None |
None |
The new product line is approved by the FDA to treat Zinc deficiency. It is administered intravenously as part of a parental nutrition regiment. It is estimated that the volume of patients that receive parental nutrition is over 290,000 hospital stays per year and that an additional 25,000 patients receive parental nutrition at home. If we assume that each hospital stay represents one unique patient then this total is 315,000 patients annually or 26,250 per month. We do not know how many of those potential patients might be prescribed the drug. |
None |
| American Regent |
00517610325 |
ZINC SULFATE INJECTION, USP 30MG/10ML (3MG/ML), PKG OF 25 |
2020-01-28 |
2107.5000 |
We do not have plans to conduct any substantial marketing activities related to the new product. We do not have any plans to conduct any direct-to-consumer advertising for the product. Our marketing efforts to promote the new drug to physicians and other health care professionals are limited to marketing on our website as well as a digital announcement to announce the availability of the new product. The prices negotiated with customers are confidential and not in the public domain or publicly available. American Regent sells its products directly to wholesalers, distributors and closed door pharmacies. American Regent also sells it product indirectly to several entities, including independent pharmacies, managed care organizations, hospitals, etc. These customers, called, "indirect customers," purchase our products primarily through our wholesale customers. The Product has not yet launched in any international jurisdiction. |
None |
26250 |
None |
None |
None |
None |
None |
None |
The new product line is approved by the FDA to treat Zinc deficiency. It is administered intravenously as part of a parental nutrition regiment. It is estimated that the volume of patients that receive parental nutrition is over 290,000 hospital stays per year and that an additional 25,000 patients receive parental nutrition at home. If we assume that each hospital stay represents one unique patient then this total is 315,000 patients annually or 26,250 per month. We do not know how many of those potential patients might be prescribed the drug. |
None |
| American Regent |
00517610125 |
Zinc Sulfate Injection, USP 1mg/mL 10mL |
2020-05-18 |
701.2500 |
We do not intend to engage in, nor have we engaged in to date, any substantial marketing activities relating to the Zinc Sulfate Products in the U.S. or internationally. Our marketing efforts to promote the new drug are generally limited to marketing on our website as well as digital announcements (including those at professional society events) to announce the availability of the new Zinc Sulfate Products. Our pricing plans are not in the public domain. |
None |
315000 |
None |
None |
None |
None |
None |
None |
We provide the following comment regarding the patient estimate: The new product line is approved by the FDA for adult and pediatric patients, as a source of zinc for parenteral nutrition, when oral or enteral nutrition is not indicated. It is administered intravenously as part of a parental nutrition regimen. It is estimated that the volume of patients that receive parental nutrition is over 290,000 hospital stays per year and that an additional 25,000 patients receive parental nutrition at home. If we assume that each hospital and each home stay represents one unique patient then this total is 315,000 patients annually. We do not know how many of those potential patients might be prescribed the drug.
We provide the following comment regarding the acquisition fields: This product was not acquired and the acquisition fields are not applicable. We provide the following general comment: We have limited the information included in this submission to that which is otherwise in the public domain or publicly available, as the California requirements permit. |
None |
| Amgen |
55513067001 |
AVSOLA 100mg Vial |
2020-07-06 |
500.0000 |
United States: There will be no direct-to-consumer marketing for AVSOLA such as TV ads, magazine or journal ads. The only platforms directed to patients is patient education brochure and a section of the AVSOLA.com website entitled “For Patients – Getting to Know AVSOLA”. This content is designed to educate patients about the 8 inflammation diseases aligned with the AVSOLA indications and potential treatment with AVSOLA, including important safety information.
Promotional activities to physicians will include professional detailing by Amgen sales representatives. Amgen is utilizing its existing inflammation sales force to educate health care professionals about AVSOLA, including the requirements for establishing biosimilarity to the reference product, Remicade, and important safety information. Professional detailing entails resources such as a core visual aid and promotional leave-behind literature. There is no free drug or sample program. Amgen also contracts with payors and providers such a hospitals and clinics to offer AVSOLA at a competitive price and ensure access to the product for appropriate patients.
AVSOLA’s Wholesale Acquisition Cost (WAC, sometimes referred to as list price) will be lower than its reference product, Remicade. The WAC of AVSOLA has been set at $50.00 per 10 mg or $500.00 per 100 mg single-dose vial, 57 percent less than the WAC of Remicade. |
None |
12800000 |
None |
None |
None |
None |
None |
None |
Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis, affecting more than 1.3 million Americans.Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disease of the gastrointestinal tract that mostly affect patients in their late adolescence and early adulthood. In 2018, the U.S. prevalence of CD and UC was ~900K and ~1.0M respectively. The National Psoriasis Foundation states more than 8M Americans have psoriasis, and CDC’s NHANES estimates that 6.7 million adults have psoriasis. Current estimates of the prevalence of ankylosing spondylitis in the United States range between 0.2% and 0.5%, or an estimated 0.6-1.6 million (based on 328M US population). |
None |
| Amneal Pharmaceuticals |
69238148803 |
Deferasirox Tablets 360mg |
2020-01-02 |
837.6100 |
This is a generic product that is not marketed. |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Amneal is limiting its response to that which is otherwise in the public domain or publicly available. The estimated average number of patients per month is unknown to Amneal. Amneal did not acquire this product. |
None |
| Amneal Pharmaceuticals |
69238173102 |
Pyridostigmine Bromide Oral Solution, USP 60mg/5mL |
2020-01-17 |
1071.5400 |
This is a generic product that is not marketed. |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Amneal is limiting its response to that which is otherwise in the public domain or publicly available. The estimated average number of patients per month is unknown to Amneal. Amneal did not acquire this product. |
None |
| Amneal Pharmaceuticals |
60219168101 |
Fluphenazine HCl 10mg |
2020-07-09 |
869.9000 |
This is a generic product that is not marketed. |
None |
1500000 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Amneal is limiting its response to that which is otherwise in the public domain or publicly available. The estimated average number of patients per month is unknown to Amneal. Amneal did not acquire this product. |
None |
| Amneal Pharmaceuticals |
60219168001 |
Fluphenazine HCl 5mg |
2020-07-09 |
689.9500 |
This is a generic product that is not marketed. |
None |
1500000 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Amneal is limiting its response to that which is otherwise in the public domain or publicly available. The estimated average number of patients per month is unknown to Amneal. Amneal did not acquire this product. |
None |
| Amneal Pharmaceuticals |
60219162101 |
Metyrosine Capsule 250mg (100 in 1 BOTTLE) |
2020-07-27 |
35005.3900 |
This is a generic product that is not marketed. |
None |
41 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Amneal is limiting its response to that which is otherwise in the public domain or publicly available. The estimated average number of patients per month is unknown to Amneal. Amneal did not acquire this product. |
None |
| Amneal Pharmaceuticals |
69238173002 |
Naproxen 125MG/5ML |
2020-08-03 |
896.4400 |
This is a generic product that is not marketed. |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Amneal is limiting its response to that which is otherwise in the public domain or publicly available. The estimated average number of patients per month is unknown to Amneal. Amneal did not acquire this product. |
None |
| Amneal Pharmaceuticals |
60219150201 |
Phenoxybenzamine HCl |
2020-10-27 |
3000.0000 |
This is a generic product that is not marketed. |
None |
1000000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Apotex Corp |
60505619702 |
SIROLIMUS O/SLN |
2020-05-22 |
1052.6200 |
Market analysis efforts are not performed at this level. The macro approach applied is evaluation of aggregated scripts in the market basket, by quarter, for the therapeutic class of the drug. Please note figured entered into the Estimated Avg. Number of Patients per month, is the monthly average aggregated scripts for this product in the market basket analyzed for launch. |
None |
23401 |
None |
None |
None |
None |
None |
None |
Apotex received FDA approval for the drug. |
None |
| AstraZeneca |
00310061060 |
Name- Koselugo (selumetinib) Dosage- 25mg/m2 Form- Capsules: 10mg 60 count bottle |
2020-04-10 |
4362.0000 |
AstraZeneca will engage 2 sales representatives to cover the state of California. Patient brochures as well as therapy management guides, may be left behind in offices for informational purposes.
AstraZeneca provides online resources via KOSELUGO™ US healthcare professionals and patient websites. Patients may register for the KOSELUGO™ support program via the website which will enroll them in a digital relationship marketing program to receive materials such as welcome letters, patient brochures, etc. The KOSELUGO™ patient savings program for eligible commercially insured patients will be available for patients in California and can be found via AstraZeneca’s Product website.
The KOSELUGO™ is currently only marketed in the United States.
When setting the price of medicines AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca’s pricing decisions are based on many factors that reflect our commitment to patients and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value.
Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. |
None |
1556 |
1 |
1 |
2003-12-18 |
None |
1 |
AstraZeneca licensed Selumetinib from Array BioPharma Inc. in 2003 for a publicly undisclosed amount. |
KOSELUGO™ is an orally available, inhibitor of mitogen-activated protein kinases 1 and 2 (MEK1/2) and is indicated for the treatment of pediatric patients 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). |
None |
| AstraZeneca |
00310062560 |
Name- Koselugo (selumetinib) Dosage- 25mg/m2 Form- Capsules: 25mg 60 count bottle |
2020-04-10 |
10905.0000 |
AstraZeneca will engage 2 sales representatives to cover the state of California. Patient brochures as well as therapy management guides, may be left behind in offices for informational purposes.
AstraZeneca provides online resources via KOSELUGO™ US healthcare professionals and patient websites. Patients may register for the KOSELUGO™ support program via the website which will enroll them in a digital relationship marketing program to receive materials such as welcome letters, patient brochures, etc. The KOSELUGO™ patient savings program for eligible commercially insured patients will be available for patients in California and can be found via AstraZeneca’s Product website.
The KOSELUGO™ is currently only marketed in the United States.
When setting the price of medicines AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca’s pricing decisions are based on many factors that reflect our commitment to patients and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value.
Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. |
None |
1556 |
1 |
1 |
2003-12-18 |
None |
1 |
AstraZeneca licensed Selumetinib from Array BioPharma Inc. in 2003 for a publicly undisclosed amount. |
KOSELUGO™ is an orally available, inhibitor of mitogen-activated protein kinases 1 and 2 (MEK1/2) and is indicated for the treatment of pediatric patients 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). |
None |
| AuroMedics Pharma LLC |
55150031825 |
Chlorpromazine Hydrochloride Injection USP, Ampules 25mg/1mL - 25s |
2020-09-01 |
722.2500 |
we plan to market the drug to hospital customers. |
None |
500000 |
None |
None |
2020-07-07 |
0.0000 |
1 |
acquisition price is proprietary |
number of patients is an ESTIMATE. we do not know how many people will be admitted to a hospital and will require treatment with this drug. additionally, there are 2 manufacturers of the injectable form of chlorpromazine and 6 manufacturers of the ORAL form (which we can assume is the preferred treatment). |
None |
| AuroMedics Pharma LLC |
55150031925 |
Chlorpromazine Hydrochloride Injection USP, Ampules 50mg/2mL - 25s |
2020-09-01 |
827.5000 |
we plan to market the drug to hospital customers. |
None |
500000 |
None |
None |
2020-07-07 |
0.0000 |
1 |
acquisition price is proprietary |
number of patients is an ESTIMATE. we do not know how many people will be admitted to a hospital and will require treatment with this drug. additionally, there are 2 manufacturers of the injectable form of chlorpromazine and 6 manufacturers of the ORAL form (which we can assume is the preferred treatment). |
None |
| AvKare |
50268016515 |
Chlorpromazine Tab 100mg |
2020-04-01 |
725.2600 |
This drug is marketed as a typical generic drug would be, through the use of wholesalers to distributor the product. There is not a significant marketing campaign or active patient facing marketing. |
None |
274 |
None |
None |
None |
None |
None |
None |
This is a generic drug - acquisition price doesn't appear to be relevant since it's not a typical situation in which there was a one time purchase payment for the development/acquisition rights to manufacturer the drug.
Monthly usage based on AvKare's expected sale volume and patient base. This is a generic drug - AvKare does not have information related to overall market usage. |
None |